Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Cardiff Oncology Inc (NASDAQ: CRDF) was $2.91 for the day, down -0.34% from the previous closing price of $2.92. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 1.0 million shares were traded. CRDF stock price reached its highest trading level at $2.93 during the session, while it also had its lowest trading level at $2.83.
Ratios:
Our analysis of CRDF’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $19. On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50. On September 06, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $8.Craig Hallum initiated its Buy rating on September 06, 2024, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 30 ’25 when PACE GARY W bought 275,000 shares for $2.45 per share. The transaction valued at 673,750 led to the insider holds 1,330,676 shares of the business.
PACE GARY W bought 15,000 shares of CRDF for $36,750 on Jul 30 ’25. The Director now owns 1,345,676 shares after completing the transaction at $2.45 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 196019232 and an Enterprise Value of 136438240. For the stock, the TTM Price-to-Sale (P/S) ratio is 392.03 while its Price-to-Book (P/B) ratio in mrq is 4.00. Its current Enterprise Value per Revenue stands at 272.332 whereas that against EBITDA is -2.558.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.40, which has changed by -0.32718897 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $4.99, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 28.11%, while the 200-Day Moving Average is calculated to be 4.77%.
Shares Statistics:
CRDF traded an average of 872.14K shares per day over the past three months and 1275660 shares per day over the past ten days. A total of 67.09M shares are outstanding, with a floating share count of 61.36M. Insiders hold about 8.91% of the company’s shares, while institutions hold 31.16% stake in the company. Shares short for CRDF as of 1764288000 were 15589278 with a Short Ratio of 17.87, compared to 1761868800 on 14251146. Therefore, it implies a Short% of Shares Outstanding of 15589278 and a Short% of Float of 23.75.
Earnings Estimates
The dynamic stock of Cardiff Oncology Inc (CRDF) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.16 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.76 and -$0.84 for the fiscal current year, implying an average EPS of -$0.78. EPS for the following year is -$0.76, with 6.0 analysts recommending between -$0.55 and -$0.97.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $500k, while the lowest revenue estimate was $300k, resulting in an average revenue estimate of $455.56k. In the same quarter a year ago, actual revenue was $683k
